全球PET放射性示踪剂市场规模、份额、趋势和成长分析报告（2026-2034年）

预计 PET 放射性追踪剂市场将从 2025 年的 26.3 亿美元成长到 2034 年的 56.5 亿美元，2026 年至 2034 年的复合年增长率为 8.84%。

由于正子断层扫描（PET）在肿瘤学、神经病学和心臟病学诊断的应用日益广泛，全球PET放射性示踪剂市场正在扩张。全球癌症发生率的上升以及对后续观察复杂的疾病。

放射性药物研发的进步和分子影像研究的扩展进一步增强了市场动态。核子医学基础设施投资的增加以及PET/CT等混合影像系统的日益普及，也推动了市场需求的成长。此外，正在进行的探索新型标靶成像示踪剂的临床研究，也扩大了放射性药物的应用范围。

随着个人化医疗和精准诊断的重要性日益凸显，未来前景一片光明。开发具有更高特异性和更短半衰期的新型示踪剂将提升临床疗效。随着医疗系统持续投资于先进诊断技术，PET放射性追踪剂市场预计将在全球范围内保持持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球PET放射性示踪剂市场：依放射性示踪剂类型划分

• 市场分析、洞察与预测
• F-18（FDG18）
• Ga-68（FAPI）
• 其他的

第五章 全球PET放射性示踪剂市场：依应用划分

• 市场分析、洞察与预测
• 癌症
• 心臟病
• 消化器官系统
• 内分泌
• 神经系统疾病
• 其他的

第六章 全球PET放射性示踪剂市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 诊断中心
• 其他的

第七章 全球PET放射性示踪剂市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • ABX Advanced Biochemical Compounds GmbH（Cambridge Isotope Laboratories Inc.）
  • Blue Earth Diagnostics
  • Cardinal Health
  • Eli Lilly And Company
  • GE Healthcare
  • IBA Radiopharma Solutions
  • Jubilant Pharma Limited
  • Lantheus Holdings Inc
  • Siemens Healthineers AG
  • Yantai Dongcheng Pharmaceutical Group Co. Ltd

The PET Radiotracer Market size is expected to reach USD 5.65 Billion in 2034 from USD 2.63 Billion (2025) growing at a CAGR of 8.84% during 2026-2034.

The global PET radiotracer market is expanding due to the increasing use of positron emission tomography in oncology, neurology, and cardiology diagnostics. Growing cancer incidence worldwide and rising demand for early disease detection are major drivers supporting market growth. PET radiotracers enable high-precision imaging, helping physicians diagnose and monitor complex medical conditions effectively.

Advancements in radiopharmaceutical development and growing research in molecular imaging are further strengthening market dynamics. Increased investments in nuclear medicine infrastructure and rising adoption of hybrid imaging systems such as PET/CT are contributing to demand expansion. Additionally, ongoing clinical research exploring new tracers for targeted imaging is broadening application scope.

Future prospects appear promising as personalized medicine and precision diagnostics gain importance. Development of novel tracers with improved specificity and shorter half-lives will enhance clinical efficiency. As healthcare systems continue investing in advanced diagnostic technologies, the PET radiotracer market is expected to witness sustained growth globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Radiotracer Type

• F-18 (FDG18)
• Ga-68 (FAPI)
• Others

By Application

• Cancer
• Heart Disease
• Gastrointestinal
• Endocrine
• Neurological Disorders
• Others

By End-user

• Hospitals
• Diagnostic Centers
• Others

COMPANIES PROFILED

• ABX advanced biochemical compounds GmbH Cambridge Isotope Laboratories Inc, Blue Earth Diagnostics, Cardinal Health, Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings Inc, Siemens Healthineers AG, Yantai Dongcheng Pharmaceutical Group Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PET RADIOTRACER MARKET: BY RADIOTRACER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Radiotracer Type
• 4.2. F-18 (FDG18) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ga-68 (FAPI) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PET RADIOTRACER MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Heart Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Endocrine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PET RADIOTRACER MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PET RADIOTRACER MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Radiotracer Type
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Radiotracer Type
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Radiotracer Type
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Radiotracer Type
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Radiotracer Type
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PET RADIOTRACER INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.)
  • 9.2.2 Blue Earth Diagnostics
  • 9.2.3 Cardinal Health
  • 9.2.4 Eli Lilly And Company
  • 9.2.5 GE Healthcare
  • 9.2.6 IBA Radiopharma Solutions
  • 9.2.7 Jubilant Pharma Limited
  • 9.2.8 Lantheus Holdings Inc
  • 9.2.9 Siemens Healthineers AG
  • 9.2.10 Yantai Dongcheng Pharmaceutical Group Co. Ltd